GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)

6 Months Ended

Apr. 30, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2020:



	Life Sciences and Applied Markets			Diagnostics and Genomics			Agilent CrossLab			Total
	(in millions)
Goodwill as of October 31, 2019	$	1,438		$	1,594		$	561		$	3,593
Foreign currency translation impact	(4		)	(4		)	(3		)	(11		)
Goodwill as of April 30, 2020	$	1,434		$	1,590		$	558		$	3,582

The components of other intangible assets as of April 30, 2020 and October 31, 2019 are shown in the table below:



	Purchased Other Intangible Assets
	Gross Carrying Amount		Accumulated Amortization		Net Book Value
	(in millions)
As of October 31, 2019
Purchased technology	$	1,413	$	763	$	650
Backlog	5		5		—
Trademark/Tradename	196		102		94
Customer relationships	329		87		242
Third-party technology and licenses	28		22		6
Total amortizable intangible assets	1,971		979		992
In-Process R&D	115		—		115
Total	$	2,086	$	979	$	1,107
As of April 30, 2020
Purchased technology	$	1,412	$	810	$	602
Trademark/Tradename	196		110		86
Customer relationships	328		123		205
Third-party technology and licenses	28		23		5
Total amortizable intangible assets	1,964		1,066		898
In-Process R&D	23		—		23
Total	$	1,987	$	1,066	$	921

During the six months ended April 30, 2020, there were no additions to goodwill and there were no additions to other intangible assets. During the six months ended April 30, 2020, other intangible assets decreased $1 million due to the impact of foreign currency translation.

In general, for United States federal tax purposes, goodwill from asset purchases is deductible; however, any goodwill created as part of a stock acquisition is not deductible.

Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three and six months ended April 30, 2020, we did not identify any triggering events or circumstances, including events due to COVID-19, which would indicate an impairment of goodwill. During the three and six months ended April 30, 2020, we recorded an impairment of in-process research and development of $90 million related to the shut-down of our sequencer development program in our diagnostics and genomics segment. There were no indicators of impairments of indefinite-lived intangible assets or goodwill during the three and six months ended April 30, 2019, respectively.

Amortization expense of intangible assets was $47 million and $95 million for the three and six months ended April 30, 2020, respectively. Amortization expense of intangible assets was $26 million and $55 million for the three and six months ended April 30, 2019, respectively.

Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2020 and for each of the five succeeding fiscal years and thereafter is estimated below:



Estimated future amortization expense:
(in millions)
Remainder of 2020	$	91
2021	$	172
2022	$	150
2023	$	107
2024	$	86
2025	$	68
Thereafter	$	224